Synthesis, Structures, and Optoelectronic Properties of Pyrene-Fused Thioxanthenes

A series of pyrene-fused thioxanthenes have been synthesized via a new concise route, and their crystal structures and photophysical properties have been fully investigated. The eight-ring fused dipyrene–thioxanthene (<b>DPTA</b>) can crystallize to monoclinic and triclinic X-ray structures, and their precursor has been isolated as two stable atropisomers with different photophysical properties. The <i>E</i>_HOMO becomes higher and the <i>E</i>_g become narrower as more thioxanthene unit being fused with pyrene

Synthesis, Structures, and Optoelectronic Properties of Pyrene-Fused Thioxanthenes

A series of pyrene-fused thioxanthenes have been synthesized via a new concise route, and their crystal structures and photophysical properties have been fully investigated. The eight-ring fused dipyrene–thioxanthene (<b>DPTA</b>) can crystallize to monoclinic and triclinic X-ray structures, and their precursor has been isolated as two stable atropisomers with different photophysical properties. The <i>E</i>_HOMO becomes higher and the <i>E</i>_g become narrower as more thioxanthene unit being fused with pyrene

Synthesis, Structures, and Optoelectronic Properties of Pyrene-Fused Thioxanthenes

A series of pyrene-fused thioxanthenes have been synthesized via a new concise route, and their crystal structures and photophysical properties have been fully investigated. The eight-ring fused dipyrene–thioxanthene (<b>DPTA</b>) can crystallize to monoclinic and triclinic X-ray structures, and their precursor has been isolated as two stable atropisomers with different photophysical properties. The <i>E</i>_HOMO becomes higher and the <i>E</i>_g become narrower as more thioxanthene unit being fused with pyrene

Synthesis, Structures, and Optoelectronic Properties of Pyrene-Fused Thioxanthenes

A series of pyrene-fused thioxanthenes have been synthesized via a new concise route, and their crystal structures and photophysical properties have been fully investigated. The eight-ring fused dipyrene–thioxanthene (<b>DPTA</b>) can crystallize to monoclinic and triclinic X-ray structures, and their precursor has been isolated as two stable atropisomers with different photophysical properties. The <i>E</i>_HOMO becomes higher and the <i>E</i>_g become narrower as more thioxanthene unit being fused with pyrene

Synthesis, Structures, and Optoelectronic Properties of Pyrene-Fused Thioxanthenes

A series of pyrene-fused thioxanthenes have been synthesized via a new concise route, and their crystal structures and photophysical properties have been fully investigated. The eight-ring fused dipyrene–thioxanthene (<b>DPTA</b>) can crystallize to monoclinic and triclinic X-ray structures, and their precursor has been isolated as two stable atropisomers with different photophysical properties. The <i>E</i>_HOMO becomes higher and the <i>E</i>_g become narrower as more thioxanthene unit being fused with pyrene

Synthesis, Structures, and Optoelectronic Properties of Pyrene-Fused Thioxanthenes

A series of pyrene-fused thioxanthenes have been synthesized via a new concise route, and their crystal structures and photophysical properties have been fully investigated. The eight-ring fused dipyrene–thioxanthene (<b>DPTA</b>) can crystallize to monoclinic and triclinic X-ray structures, and their precursor has been isolated as two stable atropisomers with different photophysical properties. The <i>E</i>_HOMO becomes higher and the <i>E</i>_g become narrower as more thioxanthene unit being fused with pyrene

DataSheet_1_Survival impact and safety of intrathoracic and abdominopelvic cytoreductive surgery in advanced ovarian cancer: a systematic review and meta-analysis.pdf

PurposeAchieving no residual disease is essential for increasing overall survival (OS) and progression-free survival (PFS) in ovarian cancer patients. However, the survival benefit of achieving no residual disease during both intrathoracic and abdominopelvic cytoreductive surgery is still unclear. This meta-analysis aimed to assess the survival benefit and safety of intrathoracic and abdominopelvic cytoreductive surgery in advanced ovarian cancer patients.MethodsWe systematically searched for studies in online databases, including PubMed, Embase, and Web of Science. We used Q statistics and I-squared statistics to evaluate heterogeneity, sensitivity analysis to test the origin of heterogeneity, and Egger’s and Begg’s tests to evaluate publication bias.ResultsWe included 4 retrospective cohort studies, including 490 patients, for analysis; these studies were assessed as high-quality studies. The combined hazard ratio (HR) with 95% confidence interval (CI) for OS was 1.92 (95% CI 1.38-2.68), while the combined HR for PFS was 1.91 (95% CI 1.47-2.49). Only 19 patients in the four studies reported major complications, and 4 of these complications were surgery related.ConclusionThe maximal extent of cytoreduction in the intrathoracic and abdominopelvic tract improves survival outcomes, including OS and PFS, in advanced ovarian cancer patients with acceptable complications.Systematic Review RegistrationPROSPERO, identifier CRD42023468096</p

DataSheet_2_Survival impact and safety of intrathoracic and abdominopelvic cytoreductive surgery in advanced ovarian cancer: a systematic review and meta-analysis.pdf

PurposeAchieving no residual disease is essential for increasing overall survival (OS) and progression-free survival (PFS) in ovarian cancer patients. However, the survival benefit of achieving no residual disease during both intrathoracic and abdominopelvic cytoreductive surgery is still unclear. This meta-analysis aimed to assess the survival benefit and safety of intrathoracic and abdominopelvic cytoreductive surgery in advanced ovarian cancer patients.MethodsWe systematically searched for studies in online databases, including PubMed, Embase, and Web of Science. We used Q statistics and I-squared statistics to evaluate heterogeneity, sensitivity analysis to test the origin of heterogeneity, and Egger’s and Begg’s tests to evaluate publication bias.ResultsWe included 4 retrospective cohort studies, including 490 patients, for analysis; these studies were assessed as high-quality studies. The combined hazard ratio (HR) with 95% confidence interval (CI) for OS was 1.92 (95% CI 1.38-2.68), while the combined HR for PFS was 1.91 (95% CI 1.47-2.49). Only 19 patients in the four studies reported major complications, and 4 of these complications were surgery related.ConclusionThe maximal extent of cytoreduction in the intrathoracic and abdominopelvic tract improves survival outcomes, including OS and PFS, in advanced ovarian cancer patients with acceptable complications.Systematic Review RegistrationPROSPERO, identifier CRD42023468096</p

miR-503 targeted L1CAM in osteosarcoma cells.

<p>(A) The sequences of miR-503 binding sites within the human L1CAM 3'UTRs and schematic reporter constructs, in this panel, L1CAM -WT represent the reporter constructs containing the entire 3'UTR sequences of L1CAM. L1CAM -MUT represent the reporter constructs containing mutated nucleotides. (B) The analysis of the relative luciferase activities of L1CAM -WT, L1CAM -MUT. The error bars are derived from triplicate expriments. (C) qRT-PCR analysis of L1CAM mRNA expression in the Mg-63 cells after treatment withmiRNA mimics or scramble or no transfection. The expression of L1CAM was normalized to GAPDH. (D) Western blot analysis ofL1CAM expression in the MG-63 cells transfected with miR-503mimics or scramble or no transfection. GAPDH was also detected as a loading control.***p<0.001.</p

L1CAM was inversely expressed with miR-503 in osteosarcoma (A) qRT-PCR analysis of L1CAM expression in 30 pair's osteosarcoma tissues and their corresponding adjacent normal tissues.

<p>The expression of L1CAM was normalized to GAPDH. (B) Relative L1CAMexpressionlevels inosteosarcoma tissues and their corresponding adjacent normal tissues.(C) The L1CAM relative mRNA expression levels were determined by qRT-PCR in Human osteosarcoma cell lines (MG-63, U2OS, SOSP-9607, and SAOS-2)) and hFOB. (D) Western blot analysis ofL1CAM expression in Human osteosarcoma cell lines (MG-63, U2OS, SOSP-9607, and SAOS-2)and hFOB. (D) Analysis of correlation of miR-503 and L1CAM expression in osteosarcoma tissues. (Two-tailed Pearson's correlation analysis, r = −0.86; p<0.01, n = 30). Data was presented as log 2 of fold change of osteosarcoma tissues relative to non-tumor adjacent tissues.***p<0.001.</p